Valneva
Signal active
Organization
Contact Information
Overview
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The comapany focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19.
It was founded in 2013 and is headquartered in Saint-herblain, France.
About
Industries
Biotechnology, Health Care, Medical
Founded
2013
Employees
501-1000
Headquarters locations
Europe
Social
N/A
Profile Resume
Valneva headquartered in Europe, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $141.5B in funding across 180 round(s). With a team of 501-1000 employees, Valneva is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Valneva, raised $53.7M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
15
Investors
0
Lead Investors
0
Total Funding Amount
$786.2M
Details
0
Valneva has raised a total of $786.2M in funding over 0 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|
Investors
Valneva is funded by 17 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Deerfield | - | FUNDING ROUND - Deerfield | 50.0M |
| Coalition for Epidemic Preparedness Innovations | - | FUNDING ROUND - Coalition for Epidemic Preparedness Innovations | 41.3M |
| Valneva | - | FUNDING ROUND - Valneva | 41.3M |
| Horizon Europe | - | FUNDING ROUND - Horizon Europe | 41.3M |
Recent Activity
There is no recent news or activity for this profile.